The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Vosaroxin plus decitabine in older AML and MDS patients – a phase II study
Vosaroxin in combination with decitabine is well-tolerated and effective in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS) according to results from a phase II study (NCT01893320) published in Haematologica by Naval Daver and colleagues from The University of Texas MD Anderson Cancer Center, Houston, Texas.1
In this phase II non-randomized study, Daver et al. aimed to assess whether the addition of vosaroxin (anti-cancer quinolone derivative that inhibits DNA topoisomerase II) to decitabine can improve the Overall Response Rate (ORR) and Overall Survival (OS) of older AML or high-risk MDS patients compared to established outcomes with decitabine alone while maintaining an acceptable safety profile.
Sixty-five (median age = 69 years) newly diagnosed AML (n = 58) and high-risk MDS (n = 7) patients were enrolled. Initially, 22 patients were administered decitabine 20mg/m2 on days 1–5 and vosaroxin 90mg/m2 on days 1 and 4. However, there was a high incidence of mucositis hence amendment of the protocol. The remaining 42 patients were administered decitabine 20mg/m2 on days 1–5 and vosaroxin 70mg/m2 on days 1 and 4.
The key results of the study were:
- ORR in all patients; 74%
- Median OS in all patients; 9.8 months
- Median OS of patients treated with 70mg/m2 and 90mg/m2 vosaroxin; 14.6 vs 5.5 months; P = 0.007
- Median OS significantly improved in responders who achieved Minimal Residual Disease (MRD)-negative status (21/39) compared to MRD-positive responders (18/39); 34.0 vs 8.3 months, P < 0.001
- Most common treatment-related Adverse Effects (AEs) was mucositis, which significantly reduced in patients administered 70mg/m2 vosaroxin compared to 90mg/m2 (grade 1–2 mucositis, 30% vs 59%, respectively, P = 0.02)
- 8-week mortality rate in patients that received 70mg/m2 and 90mg/m2 vosaroxin; 9% vs 23%, P = 0.14
In previous studies, decitabine monotherapy administered at 20mg/m2 in an extended 10-day regimen was shown to result in an ORR of 64%, an OS of 13.7 months, and an 8-week mortality of 15% in older AML patients.2
Daver et al. concluded by stating that “the combination of vosaroxin with decitabine achieves a higher response rate with an equivalent 8-week mortality to that expected with decitabine”. The authors proposed that a prospective randomized study comparing vosaroxin with decitabine with existing regimens should be carried out in older patients with AML.
Abstract
Vosaroxin is an anti-cancer quinolone derived DNA topoisomerase II inhibitor. We investigated vosaroxin with decitabine in patients ≥ 60 years of age with newly diagnosed acute myeloid leukemia (AML) (n=58) or myelodysplastic syndrome (MDS) (≥ 10% blasts) (n=7) in a phase 2 non-randomized trial. The initial 22 patients received vosaroxin 90 mg/m2 on Days 1 and 4 with decitabine 20 mg/m2 Days 1-5 every 4-6 weeks for up to 7 cycles. Due to high incidence of mucositis the subsequent 43 patients received vosaroxin 70 mg/m2 Days 1 and 4. Sixty-five patients with median age 69 years (range 60-78), secondary AML/MDS (22%), adverse karyotype (35%), TP53 mutation (20%) are evaluable. The overall response rate (ORR) was 74% including complete remission (CR) in 31 (48%), complete remission with incomplete platelet recovery (CRp) in 11 (17%), and complete remission with incomplete count recovery (CRi) in 6 (9%). The median number of cycles to response was 1 (1-4). The median duration of response was 9.9 months (0.5-32.0). The ORR among adverse karyotype (n=23) and TP53 mutated (n=13) patients was 65% and 77%, respectively. Grade 3/4 mucositis was noted in 17% of all patients. We compared outcomes between the 70 mg/m2 and the 90 mg/m2 induction doses of vosaroxin. The 70 mg/m2 induction dose of vosaroxin was associated with similar ORR (74% versus 73%) and CR rate (51% versus 41%, P=0.44), reduced incidence of mucositis (30% versus 59%, P=0.02), reduced 8-week mortality (9% versus 23%; P=0.14), and improved median overall survival (OS) (14.6 months versus 5.5 months, P=0.007). MRD-negative status by multiparametric flow-cytometry at response (+/- 3 months) was achieved in 21 of 39 (54%) evaluable responders and was associated with improved median OS (34.0 months versus 8.3 months, P=0.023). The combination of vosaroxin with decitabine is effective and well tolerated at 70 mg/m2 and warrants randomized prospective evaluation. ClinicalTrials.gov: NCT01893320
References